Vise Technologies Inc. Purchases Shares of 2,754 iShares Biotechnology ETF $IBB

Vise Technologies Inc. purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 2,754 shares of the financial services provider’s stock, valued at approximately $348,000.

Other hedge funds have also recently modified their holdings of the company. Ramirez Asset Management Inc. acquired a new position in iShares Biotechnology ETF in the first quarter valued at approximately $26,000. Berkshire Money Management Inc. purchased a new position in iShares Biotechnology ETF during the second quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of iShares Biotechnology ETF in the second quarter valued at about $31,000. Trust Co. of Toledo NA OH purchased a new stake in shares of iShares Biotechnology ETF during the second quarter worth about $32,000. Finally, Security National Bank purchased a new stake in shares of iShares Biotechnology ETF during the second quarter worth about $38,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.5%

Shares of iShares Biotechnology ETF stock opened at $164.19 on Monday. iShares Biotechnology ETF has a twelve month low of $107.43 and a twelve month high of $166.29. The firm’s 50-day moving average price is $151.00 and its 200 day moving average price is $137.11.

iShares Biotechnology ETF Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Investors of record on Tuesday, September 16th were paid a dividend of $0.0828 per share. This represents a $0.33 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend was Tuesday, September 16th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.